DDInter5 DDInter1676
Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1).[L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. Although approved for the treatment of rheumatoid arthritis, Repligen has entered a slightly different formulation of CTLA4-Ig into clinical trials (RG2077).
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Abatacept {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Abatacept {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Abatacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Omacetaxine mepesuccinate
Abatacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alemtuzumab
Abatacept {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Abatacept {u} may lead to a major life threatening interaction when taken with {v} Natalizumab
Abatacept may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Abatacept may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Abatacept may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Abatacept may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab
Abatacept may lead to a major life threatening interaction when taken with Certolizumab pegol
Abatacept may lead to a major life threatening interaction when taken with Natalizumab